OMCL Stock Recent News

Omnicell, Inc. (NASDAQ:OMCL ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President of Investor Relations Nchacha E. Etta - Executive VP & CFO Randall A.

The mean of analysts' price targets for Omnicell (OMCL) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns.

Omnicell (OMCL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.51 per share a year ago.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Second Quarter 2025 Results.

Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025.

OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?